My Treatment Approach: HER2+ Breast Cancer : Episode 3

Opinion

Video

May 28, 2024

First-Line HER2+ Metastatic Breast Cancer Trials in Focus

Author(s):

Heather McArthur, MD, emphasizes the influence of recent and ongoing clinical trials, specifically DESTINY-Breast09 and HER2CLIMB-05, in steering the treatment paradigm in 1st-line HER2-positive metastatic breast cancer.

EP: 1.The Role of HER2 in Breast Cancer and Treatment Goals for HER+ Metastatic Breast Cancer Patients

EP: 2.Evolution of the HER2+ Metastatic Breast Cancer Treatment Landscape

Now Viewing

EP: 3.First-Line HER2+ Metastatic Breast Cancer Trials in Focus

EP: 4.Case Study: Treatment Sequencing for a 62 Year Old Woman with HER2+ Metastatic Breast Cancer After Progression on T-DXd

EP: 5.Evidence-Based Sequencing for HER2+ mBC After Progression: Clinical Trial Data and NCCN Guideline Updates

EP: 6.Managing Adverse Events and Toxicities HER2+ Metastatic Breast Cancer

EP: 7.TKI Regimens and Other Novel Approaches in Later Line Treatment of HER2+ mBC Setting

EP: 8.Case Study of a 54-Year-Old Woman With HER2+ Metastatic Breast Cancer and Brain Metastases: Optimal Treatment Approaches

EP: 9.Exploring the Latest Updates from the HER2CLIMB Trial Evaluating Tucatinib in Patients with Brain Metasteses

EP: 10.Managing Brain Metastases in HER2+ Metastatic Breast Cancer: Clinical Trial Data and Multidisciplinary Approaches

EP: 11.Evolving Treatment Paradigm in HER+ Breast Cancer: Future Directions

Related Content

Kelly K. Hunt, MD, FACS, FSSO, of MD Anderson Cancer Center

January 3rd 2025

One Surgeon’s Spirit and Brilliance Lift a Whole Community

January 1st 2025

DESTINY-Breast06 Data Demonstrate the Role of T-DXd in HER2-Low and -Ultralow Breast Cancer: With Chandler Park, MD; and Guiseppe Curigliano, MD, PhD

NCCN: Image by Kellie Ehrmann/MJH Life Sciences using AI

December 31st 2024

Critical Recent NCCN Guideline Updates Affect Dozens of Malignancies

James J. Harding, MD, director, Early Drug Development, Memorial Sloan Kettering Cancer Center

December 30th 2024

FDA Approval Insights: Zanidatamab in Pretreated, HER2+ Biliary Tract Cancer

Carol Aghajanian, MD, of Memorial Sloan Kettering Cancer Center

December 28th 2024

Shaking Up Gynecologic Cancer Treatment With Mentorship and Patient-Centric Care

December 26th 2024

Allosteric Inhibitors Targeting PIK3CA May Reduce Treatment Toxicities in Breast Cancer